Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has received a consensus recommendation of “Hold” from the eight analysts that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $15.60.
Several equities research analysts have recently issued reports on FOMX shares. Cowen set a $30.00 price objective on shares of Foamix Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, March 1st. Cantor Fitzgerald reissued a “buy” rating and set a $15.00 price objective on shares of Foamix Pharmaceuticals in a research report on Tuesday, April 2nd. ValuEngine downgraded shares of Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, May 14th. HC Wainwright set a $12.00 price objective on shares of Foamix Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, May 28th. Finally, Barclays started coverage on shares of Foamix Pharmaceuticals in a research report on Tuesday, June 11th. They set an “overweight” rating and a $10.00 price objective for the company.
Shares of FOMX stock traded up $0.01 during trading hours on Tuesday, hitting $2.60. 2,896 shares of the company were exchanged, compared to its average volume of 266,254. The company has a 50 day moving average of $2.64. Foamix Pharmaceuticals has a 52 week low of $2.30 and a 52 week high of $7.60. The stock has a market cap of $140.97 million, a P/E ratio of -1.52 and a beta of 1.74.
In related news, Director Anna Kazanchyan sold 10,600 shares of the firm’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $2.61, for a total value of $27,666.00. Following the completion of the transaction, the director now owns 55,955 shares of the company’s stock, valued at $146,042.55. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders sold 19,911 shares of company stock valued at $62,582. 2.95% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its position in Foamix Pharmaceuticals by 29.7% in the fourth quarter. BlackRock Inc. now owns 620,816 shares of the specialty pharmaceutical company’s stock valued at $2,229,000 after purchasing an additional 142,159 shares in the last quarter. Eversept Partners LP grew its position in Foamix Pharmaceuticals by 7.7% in the fourth quarter. Eversept Partners LP now owns 294,660 shares of the specialty pharmaceutical company’s stock valued at $1,058,000 after purchasing an additional 21,093 shares in the last quarter. Stonepine Capital Management LLC lifted its stake in Foamix Pharmaceuticals by 134.7% in the fourth quarter. Stonepine Capital Management LLC now owns 1,293,177 shares of the specialty pharmaceutical company’s stock valued at $4,643,000 after acquiring an additional 742,099 shares during the last quarter. Sofinnova Investments Inc. lifted its stake in Foamix Pharmaceuticals by 24.5% in the fourth quarter. Sofinnova Investments Inc. now owns 832,293 shares of the specialty pharmaceutical company’s stock valued at $2,987,000 after acquiring an additional 163,674 shares during the last quarter. Finally, Diag Capital Management LP acquired a new stake in Foamix Pharmaceuticals in the fourth quarter valued at $960,000. 56.38% of the stock is owned by institutional investors and hedge funds.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.
See Also: What is a Fiduciary?
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.